Literature DB >> 7520683

Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis.

A Faraj1, D A Fowler, E G Bridges, J P Sommadossi.   

Abstract

2',3'-Dideoxynucleosides (ddNs) including 3'-azido-3'-deoxythymidine (AZT), 3'-fluoro-3'-deoxythymidine (FLT), 3'-amino-3'-deoxythymidine (AMT), 2',3'-dideoxycytidine (ddC), and 2',3'-didehydro-3'-deoxythymidine (D4T) were tested for their effects on proliferation and differentiation of pluripotent progenitor cells (CD34+) purified from human bone marrow cells grown in liquid cultures. These highly purified progenitor cells undergo extensive proliferation during 14 days, with a marked differentiation during the last 7 days. These differentiated cells exhibit normal morphological features in response to specific hematopoietic growth factors of both erythroid and granulocyte-macrophage lineages, as demonstrated by flow cytometry cell phenotyping. The potencies of these ddNs in inhibiting proliferation of granulocyte-macrophage lineage cells were in the order FLT > AMT = ddC > AZT >> D4T, and the potencies in inhibiting proliferation of erythroid lineage cultures were in the order FLT > AMT > AZT > ddC >> D4T. The toxic effects of ddNs assessed in these liquid cultures were in agreement with data obtained by using semisolid cultures, demonstrating the consistency of these two in vitro hematopoietic systems toward ddN toxicity. ddC was toxic to CD34+ progenitor cells and/or cells in the early stages of differentiation, whereas the inhibitory effect of AZT on the erythroid lineage was predominantly observed on a more mature population of erythroid progenitors during the differentiation process. Slot blot analysis of granulocyte-macrophage cultures demonstrated that exposure to ddC and FLT was associated with a decrease in total mitochondrial DNA (mtDNA) content, suggesting that these two ddNs inhibit mtDNA synthesis. In contrast, no difference in the ratio of nuclear DNA to mtDNA was observed in cells exposed to toxic concentrations of AZT and AMT is not associated with an inhibition of mtDNA synthesis. This human pluripotent progenitor liquid culture system should permit detailed investigations of the cellular and molecular events involved in ddN-induced hematological toxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520683      PMCID: PMC188128          DOI: 10.1128/AAC.38.5.924

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Effector studies of 3'-azidothymidine nucleotides with human ribonucleotide reductase.

Authors:  J A Harrington; W H Miller; T Spector
Journal:  Biochem Pharmacol       Date:  1987-11-01       Impact factor: 5.858

2.  3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA.

Authors:  J A Harrington; J E Reardon; T Spector
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

3.  Sequence and organization of the human mitochondrial genome.

Authors:  S Anderson; A T Bankier; B G Barrell; M H de Bruijn; A R Coulson; J Drouin; I C Eperon; D P Nierlich; B A Roe; F Sanger; P H Schreier; A J Smith; R Staden; I G Young
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

4.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

5.  Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells.

Authors:  J P Sommadossi; R F Schinazi; C K Chu; M Y Xie
Journal:  Biochem Pharmacol       Date:  1992-11-17       Impact factor: 5.858

6.  Inhibition of mammalian DNA polymerase-associated 3' to 5' exonuclease activity by 5'-monophosphates of 3'-azido-3'-deoxythymidine and 3'-amino-3'-deoxythymidine.

Authors:  E G Bridges; A Faraj; J P Sommadossi
Journal:  Biochem Pharmacol       Date:  1993-04-22       Impact factor: 5.858

7.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro.

Authors:  J P Sommadossi; R Carlisle
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

10.  Zidovudine-induced blockade of the expression and function of the erythropoietin receptor.

Authors:  S R Gogu; J S Malter; K C Agrawal
Journal:  Biochem Pharmacol       Date:  1992-09-25       Impact factor: 5.858

View more
  18 in total

Review 1.  Stavudine once daily.

Authors:  Susan M Cheer; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis.

Authors:  J L Martin; C E Brown; N Matthews-Davis; J E Reardon
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 4.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 5.  Mitochondrial toxicity and HIV therapy.

Authors:  A J White
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

6.  Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes.

Authors:  X R Pan-Zhou; E Cretton-Scott; X J Zhou; M Y Xie; R Rahmani; R F Schinazi; K Duchin; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

7.  Mitochondrial Toxicity Associated with Nucleoside Reverse Transcriptase Inhibitor Therapy.

Authors:  Cecilia M. Shikuma; Bruce Shiramizu
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

8.  In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans.

Authors:  R E Dornsife; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  The anti-human immunodeficiency virus agent 3'-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells.

Authors:  R Sundseth; S S Joyner; J T Moore; R E Dornsife; I K Dev
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  Protection and rescue from 2',3'-dideoxypyrimidine nucleoside analog toxicity by hemin in human bone marrow progenitor cells.

Authors:  D A Fowler; M Y Xie; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.